9 April 2021 (Friday) - ASH Update

 The nice people at the American Society of Hematology sent their update today. All useful stuff…

Here are the highlights in lymphomas and lymphoid neoplasia:

Examining the Blood-Brain Barrier
The prognosis for patients with non-Hodgkin lymphoma who develop central nervous system relapse is dismal, and there are few clear answers about the best prevention strategies.
Axicabtagene Ciloleucel Approved for Relapsed/Refractory Follicular Lymphoma
Based on results from the ZUMA-5 trial, the FDA’s decision makes axicabtagene ciloleucel the first CAR T-cell therapy to be approved for the treatment of indolent follicular lymphoma.
FDA Accepts sNDA for Zanubrutinib in Waldenström Macroglobulinemia
The supplemental new drug application was primarily based on safety and efficacy data from the phase III ASPEN trial comparing zanubrutinib with ibrutinib for the treatment of adult patients with WM.

No comments:

Post a Comment